Editorial Material
Oncology
Richard T. Maziarz, Jordan Gauthier
Summary: CAR T-cell therapy has revolutionized the treatment of relapsed/refractory DLBCL, but the availability of multiple products has raised questions about treatment selection and balancing toxicity with efficacy.
NATURE REVIEWS CLINICAL ONCOLOGY
(2023)
Article
Oncology
David G. Maloney, John Kuruvilla, Fei Fei Liu, Ana Kostic, Yeonhee Kim, Ashley Bonner, Yixie Zhang, Christopher P. Fox, Guillaume Cartron
Summary: This study used matching-adjusted indirect comparisons to evaluate the comparative efficacy and safety of lisocabtagene maraleucel versus axicabtagene ciloleucel in patients with relapsed or refractory large B cell lymphoma, finding that lisocabtagene maraleucel demonstrated comparable efficacy and a more favorable safety profile in this patient population.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Review
Immunology
Ilse Gille, Frans H. J. Claas, Geert W. Haasnoot, Mirjam H. M. Heemskerk, Sebastiaan Heidt
Summary: Solid organ transplantation is an effective treatment for end-stage diseases, but the need for immunosuppression can lead to serious side effects. CAR Treg therapy, specifically with HLA-A2 CAR Tregs, shows potential in promoting transplantation tolerance and improving graft survival.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Oncology
Elien De Bousser, Nico Callewaert, Nele Festjens
Summary: T cell-engaging immunotherapy aims to activate cytotoxic T cells to destroy cancer cells, while CAR T cell therapy redirects immune cells to recognize tumor antigens. Despite success, challenges such as toxicities and limited efficacy need to be addressed for the broad use of CAR T cell therapy. Research is ongoing to develop more powerful CAR T cells.
Review
Pharmacology & Pharmacy
Taewoong Choi, Yubin Kang
Summary: Although treatment outcomes for multiple myeloma patients have greatly improved in the past two decades, the disease remains incurable. New immunotherapies, including monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, and chimeric antigen receptor (CAR) T cell therapy, have emerged to treat multiple myeloma. This article provides a comprehensive review of the clinical efficacy, safety, and potential resistance mechanisms of current myeloma CAR-T therapies, with a focus on B Cell Maturation Antigen (BCMA) as the most successful target. The article also discusses novel strategies to enhance the effectiveness of myeloma CAR-T therapy.
PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Oncology
Olalekan O. Oluwole, Jenny M. H. Chen, Keith Chan, Anik R. Patel, Jeroen P. Jansen, Sam Keeping, Yan Zheng, Julia T. Snider, Frederick L. Locke
Summary: An unanchored matching-adjusted indirect comparison was used to estimate the relative treatment effects of Axi-cel and liso-cel for relapsed/refractory large B-cell lymphoma. The results suggest that Axi-cel improved survival compared to liso-cel, but with increased odds of specific adverse events.
LEUKEMIA & LYMPHOMA
(2022)
Review
Biochemical Research Methods
Cuilin Zhang, Qiuyu Zhuang, Jingfeng Liu, Xiaolong Liu
Summary: Synthetic biology is an interdisciplinary research area that uses engineering principles to design and construct biological systems for practical applications. Chimeric antigen receptor (CAR) T cells, as one of the most successful clinical applications of synthetic biology, have shown tremendous success in treating blood malignancies. However, there are still limitations to CAR T cell therapy, hence the need for innovative CAR design becomes urgent.
ACS SYNTHETIC BIOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Sachiko Hirobe, Keisuke Imaeda, Masashi Tachibana, Naoki Okada
Summary: In this study, we investigated the effects of disulphide bonding and glycosylation on the function of CAR-expressing T cells. We found that disulphide bonds and N-linked glycosylation influenced CAR expression and CAR-T cell activity, providing insights for future CAR design.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Cell Biology
Tahereh Soltantoyeh, Behnia Akbari, Amirali Karimi, Ghanbar Mahmoodi Chalbatani, Navid Ghahri-Saremi, Jamshid Hadjati, Michael R. Hamblin, Hamid Reza Mirzaei
Summary: Metastatic melanoma is a highly aggressive and difficult to treat type of skin cancer, but new therapies like CAR T cell therapy offer hope for patients. However, challenges such as off-target toxicity and therapy resistance need to be addressed through combination approaches.
Article
Hematology
Tomoyasu Jo, Satoshi Yoshihara, Yoshiki Okuyama, Keiko Fujii, Tomoko Henzan, Kaoru Kahata, Rie Yamazaki, Wataru Takeda, Yoshihiro Umezawa, Kentaro Fukushima, Takashi Ashida, Minami Yamada-Fujiwara, Ryo Hanajiri, Noboru Yonetani, Yuma Tada, Yuji Shimura, Hidekazu Nishikii, Norio Shiba, Naoya Mimura, Jun Ando, Takayuki Sato, Yasuhiro Nakashima, Junko Ikemoto, Keita Iwaki, Shin-ichiro Fujiwara, Masaki Ri, Tokiko Nagamura-Inoue, Ryuji Tanosaki, Yasuyuki Arai
Summary: In order to determine the risk factors for CAR-T cell manufacturing failure, a nationwide cohort study was conducted in Japan on patients with DLBCL who underwent tisagenlecleucel production. The study found that previous treatment with bendamustine, low platelet counts, and low CD4/CD8 T-cell ratios were significant risk factors for manufacturing failure. Repeated use of bendamustine with short washout periods prior to apheresis, low platelet counts, and low CD4/CD8 ratios were all independently associated with an increased risk of manufacturing failure.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Review
Oncology
Giuseppe Schepisi, Caterina Gianni, Michela Palleschi, Sara Bleve, Chiara Casadei, Cristian Lolli, Laura Ridolfi, Giovanni Martinelli, Ugo De Giorgi
Summary: To date, various therapeutic strategies, including immunotherapies, have been successful in prolonging the survival of breast cancer patients. Our article focuses on the application of chimeric antigen receptor-based immunotherapy in breast cancer.
Review
Biochemistry & Molecular Biology
Antonio Nenna, Myriam Carpenito, Camilla Chello, Pierluigi Nappi, Ombretta Annibali, Bruno Vincenzi, Francesco Grigioni, Massimo Chello, Francesco Nappi
Summary: CAR-T therapy has revolutionized the treatment of hematologic malignancies, but it also carries the risk of cardiotoxicity. Prompt diagnosis and treatment are crucial to improve outcomes and reduce cardiovascular complications.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biotechnology & Applied Microbiology
Christina Amatya, Melissa A. Pegues, Norris Lam, Danielle Vanasse, Claudia Geldres, Stephanie Choi, Stephen M. Hewitt, Steven A. Feldman, James N. Kochenderfer
Summary: CARs targeting SLAMF7 show promise for MM therapy due to specific expression on MM cells, and CD28-containing CARs exhibit superior anti-tumor activity compared to 4-1BB-containing CARs. Inclusion of a suicide gene in SLAMF7-targeting CAR T cells is prudent to eliminate cells expressing SLAMF7 on normal leukocytes when necessary.
Review
Oncology
Vicky Mengfei Qin, Criselle D'Souza, Paul J. Neeson, Joe Jiang Zhu
Summary: Chimeric antigen receptors (CAR) are engineered molecules that can recognize specific antigens and induce downstream signaling, primarily used in CAR-T cells to target and kill tumor cells. While CAR-T cell therapy has shown success in treating hematologic malignancies, current research is focusing on extending CAR technology to other immune cells for potential applications in solid tumors and autoimmune diseases. CAR technology is a powerful platform in immunotherapy with diverse applications beyond conventional CAR-T cells.
Review
Immunology
Long Chen, Fukun Chen, Huatao Niu, Jindan Li, Yongzhu Pu, Conghui Yang, Yue Wang, Rong Huang, Ke Li, Yujie Lei, Yunchao Huang
Summary: CAR-T cell therapy is a novel immunotherapy strategy that has been successfully used against both hematological tumors and solid tumors. Despite some challenges, CAR-T cell treatment still holds great promise.
FRONTIERS IN IMMUNOLOGY
(2022)
